Industry
ImmuPharma
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Success Rate
100.0%
+13.4% vs industry average
Late-Stage Pipeline
100%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 3
2(100.0%)
2Total
Phase 3(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT02504645Phase 3Completed
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Role: lead
NCT03427151Phase 3Completed
Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Role: lead
All 2 trials loaded